BLA 761115 · Immunomedics INC
Trodelvy
Sacituzumab Govitecan-Hziy · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 22, 2020
Approved uses
8
Original approval plus efficacy supplements
Registered trials
151
23 Phase 3, 71 recruiting
FAERS reports
4,834
4,329 serious, 1,014 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEUTROPENIA AND DIARRHEA TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia [see Dosage and Administration (2.4) ] . Initiate anti-infective treatment in patients with febrile neutropenia without delay [see Warnings and Precautions (5.1) ]. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide [see Warnings and Precautions (5.2) ]. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses [see Dosage and Administration...
What it is approved for
From the label in effect Jun 24, 2026.
TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable...
Mechanism: Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2026 Supplement 64 · Efficacy LetterLabel
- Jun 24, 2026 Supplement 63 · Efficacy LetterLabel
- Nov 22, 2024 Supplement 58 · Efficacy · priority review LabelLetter
- Feb 3, 2023 Supplement 35 · Efficacy · priority review LabelLetter
- Apr 13, 2021 Supplement 9 · Efficacy · priority review LabelLetter
- Apr 7, 2021 Supplement 13 · Efficacy · priority review LetterLabel
- Apr 7, 2021 Supplement 5 · Efficacy · priority review LetterLabel
- Apr 22, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
- TRODELVY · SACITUZUMAB GOVITECAN-HZIY 180MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sacituzumab Govitecan" as an intervention, any sponsor and status, largest first.
Gilead SciencesGilead Sciences (GILD)
NCT05633654 · 1,514 participants (planned) · Start Dec 12, 2022 · Primary completion Jun 2027
Drug: Sacituzumab govitecan-hziy (SG); Pembrolizumab and 1 more · For: Triple Negative Breast Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 378 sites in all
- Sacituzumab Govitecan in Primary HER2-negative Breast CancerPivotal-lookingActive, not recruiting
GBG Forschungs GmbHAcademic, hospital or other
NCT04595565 · 1,332 participants (planned) · Start Oct 28, 2020 · Primary completion Mar 30, 2027
Drug: Capecitabine; Carboplatin and 2 more · For: HER2-negative Breast Cancer; Triple Negative Breast Cancer
Sites: Graz, Austria; Innsbruck, Austria; Linz, Austria · 163 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsActive, not recruiting
DualityBio Inc.Industry
NCT05438329 · 1,123 participants (planned) · Start Jul 19, 2022 · Primary completion Aug 13, 2027
Drug: DB-1305/BNT325; BNT327 · For: Advanced Solid Tumor
Sites: Bullhead City, Arizona; Cerritos, California; La Jolla, California · 93 sites in all
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerPivotal-lookingNot yet recruiting
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT07178730 · 765 participants (planned) · Start Aug 30, 2026 · Primary completion Mar 31, 2033
Drug: Sacituzumab govitecan; Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] and 1 more · For: Breast Cancer; Triple-negative Breast Cancer
Sites: Heilbronn, Germany; Weinheim, Germany; Augsburg, Germany · 26 sites in all
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT04527991 · 711 participants · Start Jan 13, 2021 · Primary completion Jul 4, 2025
Drug: Sacituzumab Govitecan-hziy; Paclitaxel and 2 more · For: Locally Advanced or Metastatic Unresectable Urothelial Cancer
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 234 sites in all
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06801834 · 695 participants (planned) · Start Apr 4, 2025 · Primary completion Oct 2029
Drug: Sacituzumab Govitecan (SG); Topotecan and 2 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Anaheim, California · 219 sites in all
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05840211 · 654 participants (planned) · Start May 8, 2023 · Primary completion Apr 2028
Drug: Sacituzumab Govitecan-hziy; Paclitaxel and 2 more · For: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer
Sites: Chandler, Arizona; Los Angeles, California; Palo Alto, California · 288 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression1,368
- diarrhoea615
- neutropenia549
- death491
- nausea281
- fatigue273
- triple negative breast cancer229
- febrile neutropenia219
- asthenia217
- off label use207
- alopecia176
- inappropriate schedule of product administration170
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 112 |
| 2021 | 397 |
| 2022 | 1,248 |
| 2023 | 579 |
| 2024 | 714 |
| 2025 | 967 |
| 2026 | 815 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trodelvy (Sacituzumab Govitecan-Hziy)
2024 spending
$6.2M
Beneficiaries
67
319 claims
Per beneficiary
$92,888
$2,399.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $852,092 |
| 2021 | $1,908,219 |
| 2022 | $3,041,189 |
| 2023 | $4,567,680 |
| 2024 | $6,223,470 |
Part B: Trodelvy (Sacituzumab Govitecan-Hziy) · HCPCS J9317
2024 spending
$272M
Beneficiaries
3,300
28,257 claims
Per beneficiary
$82,521
2024 ASP limit $34.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $96,029,681 |
| 2022 | $156,284,895 |
| 2023 | $230,777,754 |
| 2024 | $272,318,588 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Cortés J, Punie K, Barrios C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Tolaney SM, de Azambuja E, Kalinsky K, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS, Bardia A, Marmé F, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
Bardia A, Rugo HS, Tolaney SM, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Rugo HS, Bardia A, Marmé F, et al. · J Clin Oncol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.